EMERGING ROLE OF 18FDG PET/CT IN BREAST CANCER

Maseeh uz Zaman, Nosheen Fatima, Areeba Zaman, Sidra Zaman, Unaiza Zaman

Abstract


Breast cancer (BC) is the most common cancer in women worldwide and unfortunately Pakistan is one of the countries having the highest rate. BC related mortality is higher in patients having advance disease at the time of diagnosis. Various therapeutic strategies are available which include surgery (from radical to breast conserving options), radiation therapy, hormonal therapy and targeted therapy. Precise staging of the disease and information about the phenotype of tumor (ER: estrogen receptor; progesterone receptor: PR; Human epidermal factor receptor2: HER2) is very important for selection of proper therapeutic options.  Epidemiological data have shown that young BC patients have more aggressive tumors with potential for early metastases than older patients. Similarly patients with triple negative breast cancer (ER, PR and HER2 negative) have the worst while ER+/HER2- have the best prognosis. Studies have also shown that patients with triple negative and HER2+ BC have a higher predilection for extra-skeletal metastases.




Full Text:

PDF

References


. Fatima N, Zaman M, Fatima T. Increased risk of breast cancer in multiparous and lactating women attending a breast care clinic in Pakistan: a paradigm shift? Asian Pac J Cancer Prev 2010; 11: 1219-23.

. Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55:1578–83.

. Groheux D, Giacchetti S, Espié M, Rubello D, Moretti J-L, Hindié E. Early monitoring of response to neoadjuvant chemotherapy in breast cancer with (18)F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging. 2011;38:419–25.

. Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, et al. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016;43:1937–44.

. Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the Clinical Management of Breast Cancer. Radiology 2013; 266 (2): 388-405

. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473–8.

. Groheux D, Cochet A, Humbert O, Alberini J-L, Hindié E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(Suppl 1):17S–26S.

. Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, et al. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014;55:1578–83.

. Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography

imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995–1000.

. Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA. (18)FFDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2017; 44(9):1420-27

. Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espié M, Lehmann-Che J, et al. Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426–35.

. Koolen BB, Vrancken Peeters M-JTFD, Aukema TS, Vogel WV, Oldenburg HSA, van der Hage JA, et al. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat. 2012; 131:117–26.


Refbacks

  • There are currently no refbacks.


© Copyright PJR 2008-